Treasure Island: Branch receives approval notice for the listing application of Brivaracetam active pharmaceutical ingredient.

Treasure Island announced that its Jixi branch recently received the approval notice for the listing application of the chemical raw material drug Brivaracetam issued by the National Medical Products Administration. Brivaracetam tablets are used to treat schizophrenia in adults, and the original drug was approved for listing in China in June 2024. The raw material drug is currently listed as "A" on the Drug Registration Information Publicity Platform for Raw Materials, Excipients, and Packaging Materials of the National Medical Products Administration Drug Evaluation Center. The company has accumulated approximately 7.2111 million yuan in research and development expenses for the Brivaracetam raw material drug development project. Obtaining this approval notice will further enrich the company's product line, contribute to enhancing the market competitiveness of the company's products, but pharmaceutical production and sales are influenced by various factors and uncertainties.